Can a bespoke cancer vaccine actually succeed in treating individual oncology cases?
Neon Therapeutics launched three years ago, setting out on a mission to prove that it could, and it now has enough examples of a select handful of individual responses to their neoantigen platform to gamble that investors will come in to back a $115 million IPO as they look to transition from their first exploratory human studies into advanced development work.
Over the startup period, Neon has been developing its first peptide-based individualized cancer vaccines, working with the mutations present in each case. Their work has steered them toward a set of cancers like non-small cell lung cancer, which have a high mutation burden and a rich set of individual antigen targets to select from.
By zeroing in on these neoantigens, they say, they can make the first generation of checkpoint inhibitors — designed to unleash a swarm of T cells on cancer cells — far more effective. But groundbreaking new technologies like these also require their own manufacturing base, and they won’t come cheap.
Third Rock launched Neon Therapeutics with a high council of prominent scientists from Dana-Farber, MIT and elsewhere. The advisory group included Eric Lander from the Broad Institute of MIT and Harvard, MD Anderson’s Jim Allison and Catherine Wu with Dana-Farber. In true Third Rock style they recruited Novartis vet High O’Dowd to come in and take the helm, and the VC group still owns 44.4% of the equity.